3',4'-Methylenedioxy-α-pyrrolidinopropiophenone

3',4'-Methylenedioxy-α-pyrrolidinopropiophenone (MDPPP) is a stimulant designer drug. It was sold in Germany in the late 1990s and early 2000s as an ingredient in imitation ecstasy (MDMA) pills.[1] It shares a similar chemical structure with α-PPP and MDPV,[2][3][4] and has been shown to have reinforcing effects in rats.[5]

3',4'-Methylenedioxy-α-pyrrolidinopropiophenone
Clinical data
Routes of
administration		oral, insufflation, Vaporization, IV, rectal, sublingual
Legal status
Legal status
Pharmacokinetic data
MetabolismHepatic
ExcretionPrimarily Urine (Renal)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC14H17NO3
Molar mass247.294 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture

Metabolism

MDPPP appears to have a similar metabolic fate as MDPV.[4]

As of October 2015 MDPPP is a controlled substance in China.[6]

gollark: Anyway, it doesn't matter, I've pushed a version which limits results to 5.
gollark: I have *double* the DDRness!
gollark: DDR2? Madness.
gollark: "Store that in the function"...?
gollark: Like I said, it's *probably* fine, just slight interoperability between the command handling system and callback handling.

See also

References
  1. Springer D, Fritschi G, Maurer HH (August 2003). "Metabolism and toxicological detection of the new designer drug 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 793 (2): 377–88. doi:10.1016/S1570-0232(03)00350-7. PMID 12906913.
  2. Maurer HH, Kraemer T, Springer D, Staack RF (April 2004). "Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis". Therapeutic Drug Monitoring. 26 (2): 127–31. doi:10.1097/00007691-200404000-00007. PMID 15228152.
  3. Staack RF, Maurer HH (June 2005). "Metabolism of designer drugs of abuse". Current Drug Metabolism. 6 (3): 259–74. doi:10.2174/1389200054021825. PMID 15975043.
  4. Springer D, Staack RF, Paul LD, Kraemer T, Maurer HH (March 2005). "Identification of cytochrome P450 enzymes involved in the metabolism of 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 35 (3): 227–37. doi:10.1080/00498250400028239. PMID 16019948.
  5. Gannon BM, Galindo KI, Mesmin MP, Sulima A, Rice KC, Collins GT (May 2018). "Relative reinforcing effects of second-generation synthetic cathinones: Acquisition of self-administration and fixed ratio dose-response curves in rats". Neuropharmacology. 134 (Pt A): 28–35. doi:10.1016/j.neuropharm.2017.08.018. PMC 5809320. PMID 28811192.
  6. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.